Imatinib is not a potent anti-SARS-CoV-2 drug
Helong Zhao, Michelle Mendenhall, Michael W. Deininger
Topics & Concepts
ImatinibDrugMedicineImatinib mesylateSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)HematologyPharmacologyCancer researchVirologyCoronavirus disease 2019 (COVID-19)ImmunologyInternal medicineInfectious disease (medical specialty)Myeloid leukemiaDiseaseChronic Myeloid Leukemia TreatmentsQuinazolinone synthesis and applicationsChronic Lymphocytic Leukemia Research